ME Therapeutics Holdings Inc

ME Therapeutics Holdings Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing diagnostic solutions for medical applications.

The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

ME Therapeutics Holdings Inc has a current liquidity position characterized by a current ratio of 6.12, indicating a strong ability to meet short-term obligations with its current assets. However, the company reported negative operating cash flow of -862,350 CAD and free cash flow of -1,326,030 CAD, suggesting ongoing cash outflows from operations. The company's debt-to-equity ratio is 0.05, reflecting a low level of leverage and a conservative capital structure.

In terms of profitability, the company reported a net loss of 1,193,200 CAD and an operating loss of 1,288,290 CAD, resulting in a return on equity of -79.38% and a return on assets of -67.82%. These figures are significantly below the industry median for profitability metrics, indicating underperformance relative to its peers.

The company's revenue is not disclosed in the provided data, and there is no information on geographic or segmental revenue distribution. As a result, it is not possible to assess revenue concentration or geographic exposure at this time.

The company's growth trajectory is not clearly defined in the available data. There is no indication of revenue growth or decline, and the outlook for the current and next fiscal years is not provided. The company's capital expenditures of -216,150 CAD suggest ongoing investment in infrastructure or equipment, but the impact on future growth is unclear.

The company faces a medium liquidity risk due to its negative operating and free cash flows, despite a strong current ratio. The risk assessment also notes that net cash is negative after subtracting total debt, which could impact the company's ability to fund operations without external financing. The dilution risk is assessed as low, and there are no adjustments applied to the valuation metrics that would suggest significant dilution pressure.

There are no recent events or filings disclosed in the provided data that would indicate significant changes in the company's operations, strategy, or financial position.

- ME Therapeutics Holdings Inc is a biotechnology company focused on healthcare diagnostics. - The company has a strong current ratio but is experiencing negative operating and free cash flows. - The company's profitability metrics are significantly below the industry median, indicating underperformance. - There is no information on geographic or segmental revenue distribution, making it difficult to assess revenue concentration. - The company faces a medium liquidity risk and a low dilution risk. - There are no recent events disclosed that would indicate significant changes in the company's operations or financial position.